Experimentelle Einzeldosis-Behandlung senkt „schlechtes“ Cholesterin im ersten Versuch am Menschen um 52 %: ein präziser DNA-Editierungsansatz, bei dem die CRISPR-Technologie verwendet wird, um eine dauerhafte genetische Veränderung herbeizuführen, die das LDL-Cholesterin nach einer einzigen Behandlung dauerhaft senken könnte.

Experimental One-Dose Treatment Cuts ‚Bad‘ Cholesterol by 52% in First Human Trial

Too much ‚bad‘ cholesterol in the bloodstream – that’s the low-density lipoprotein (LDL) type – can contribute to plaque buildup in the arteries, increasing the risk of cardiovascular problems like heart attacks and strokes.

Many factors affect LDL cholesterol levels, including genetics, diet, and age, while treatments for high cholesterol can involve dietary changes and statins.

Scientists are now working on a precise DNA-editing approach, using CRISPR technology to make a permanent genetic change that could durably reduce LDL cholesterol after a single treatment.

Called CTX310, it aims to mimic a naturally occurring genetic variant that lowers LDL cholesterol via reduced expression of a liver protein called ANGPTL3.

New results from a clinical trial, led by a team from the Cleveland Clinic Coordinating Center for Clinical Research and published in the New England Journal of Medicine, suggest the approach can remain safe and effective even a year later.

https://www.nejm.org/doi/10.1056/NEJMc2609825

Hopefully beneficial. However LDL comes in 8 ish types and only a handful oxidise into plaques, need to be careful not to remove the LDL we want in the process.